What is the evidence base for NAD+?

NAD+'s evidence base sits at research level investigational. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The female physiology interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How does NAD+'s half-life affect dosing?

NAD+ has a plasma half-life of Hours; cellular pool dynamic, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1x weekly iv; daily subq at lower doses dosing at 100-1000 mg per dose explains the typical onset timeline for female hormonal and cyclical endpoints.

How does NAD+ interact with female hormonal cycling?

Cyclical hormone background influences how NAD+ is distributed, metabolised, and felt. The compound's pharmacology is directly modulated by cycle-related hormones, making phase-aware dosing meaningful. Premenopausal users should track by cycle phase for 1–2 cycles before settling on a fixed schedule; perimenopausal users benefit from integration with HRT where indicated.

How long until I see results from NAD+?

Acute effects from NAD+ appear within hours of dosing for receptor-level changes. female hormonal and cyclical endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What is the mechanism of action of NAD+?

Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60. For female hormonal and cyclical applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. The female physiology interpretation focuses on the pathway-level detail rather than on any single high-level summary.

Standard cycle for NAD+ is 8–12 weeks of 1x weekly iv; daily subq at lower doses 100-1000 mg dosing via iv/subq/intranasal/oral precursors (nr/nmn), followed by a 4 week complete off-period. The off-period is calibrated to NAD+'s Hours; cellular pool dynamic half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Home/ Compounds/ NAD+

NAD+

Women's Health

Cycle-aware, fertility-aware, perimenopause-aware: NAD+ is evaluated by women's-health clinicians on multiple axes. Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60.. The compound's pyridine nucleotide cofactor pharmacology produces measurable effects on the systems women's-health practice cares about — cycle regularity, mood, bone density, cardiovascular tone, and the perimenopausal transition. Each is examined in the sections below.

Female Physiology Applications

Cycle SupportAutoimmune SupportMenopauseHair HealthVaginal Health

Key Takeaways

Female-physiology lens: NAD+ response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 100-1000 mg 1x weekly iv; daily subq at lower doses via iv/subq/intranasal/oral precursors (nr/nmn); cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60. For women's-health applications, the mechanism is evaluated against cyclical context, fertility implications, bone remodelling, and cardiovascular tone. NAD+'s contribution to each varies; the subsections below work through these in turn.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, NAD+ is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Fertility and reproductive considerations

NAD+'s effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. NAD+'s effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Female Physiology Applications

Menopause

For menopause in female users, NAD+ is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Body Composition (Female)

Body Composition (Female) is one of the dimensions on which women track NAD+ response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Cycle Support

In the perimenopausal window, NAD+ for cycle support produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Cardiovascular (Female)

For cardiovascular (female) in female users, NAD+ is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	IV	100-1000 mg	8–12 weeks on / 4 weeks off
Conservative starter	IV	60-1000 mg	4–6 weeks initial cycle
Women's Health focus	IV	100-1000 mg	1x weekly IV; daily SubQ at lower doses
Maintenance phase	IV	70-1000 mg	Ongoing with periodic pauses

Dose timing for NAD+ is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

NAD+ stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

NAD+ + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with NAD+'s mechanism in female physiology protocols.
NAD+ + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with NAD+'s mechanism in female physiology protocols.
NAD+ + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with NAD+'s mechanism in female physiology protocols.
NAD+ + Epithalon: Identified by Khavinson in St. Pairs naturally with NAD+'s mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved by various routes for various uses; mass-dose IV is off-label

Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush.

Lens-specific safety considerations for female physiology use of NAD+: Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

NAD+ metabolism in health and disease

PMID 31738478

Supporting

NAD+ decline with aging and supplementation

PMID 31197173

NAD+ vs Related Peptides

Compound	Profile	Onset	Best For
NAD+	Pyridine nucleotide cofactor	Hours; cellular pool dynamic	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Can I use NAD+ alongside HRT?

Yes, in most cases. Integration with HRT — estrogen, progesterone, sometimes testosterone — is additive rather than competitive for most peptide compounds. Coordinating with a HRT-prescribing physician on dose timing and monitoring is the standard approach.

Will NAD+ affect contraceptive efficacy?

For most peptide compounds, contraceptive efficacy is not significantly affected. Compounds directly modulating the HPG axis (kisspeptin, gonadorelin) are exceptions and warrant alternative or additional contraceptive measures during use. NAD+'s specific interaction follows its mechanism.

Can I use NAD+ during pregnancy or while trying to conceive?

Most peptide therapeutics, including NAD+, do not have safety data supporting use during pregnancy or active conception. The default position is to discontinue at least 2–3 cycles before planned conception and to avoid throughout pregnancy and lactation unless specifically approved by a physician familiar with the indication.

Is NAD+ appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

What is NAD+?

NAD+ (also known as Nicotinamide adenine dinucleotide / β-NAD) is a small pyridine nucleotide cofactor with a molecular weight of 663 Da and a plasma half-life of Hours; cellular pool dynamic. Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60. The compound is studied primarily in the female physiology domain for the applications outlined above.

What is the standard dosing protocol for NAD+?

Conventional NAD+ dosing is 100-1000 mg 1x weekly iv; daily subq at lower doses via iv/subq/intranasal/oral precursors (nr/nmn). For female hormonal and cyclical use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Clinical Protocol

Start a NAD+ Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified NAD+ and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: 663 Da
Half-life: Hours; cellular pool dynamic
WADA: Not on prohibited list
FDA: Approved by various routes for various uses; mass-dose IV is off-label

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for NAD+ unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for NAD+

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised